» Articles » PMID: 2963246

Impact of Improved Dental Services on the Frequency of Oral Complications of Cancer Therapy for Patients with Non-head-and-neck Malignancies

Overview
Date 1988 Jan 1
PMID 2963246
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

An earlier study by our group reported a frequency of about 40% for oral problems associated with cancer therapy for patients with non-head-and-neck malignancies. Since then, we have instituted a variety of preventive and treatment protocols aimed at the aggressive management of the mouth in patients being treated for malignant disease. In the present study we evaluated the frequency and nature of oral problems associated with cancer treatment in 495 patients treated for non-head-and-neck malignancies between 1978 and 1986. Our analysis indicates that the frequency of oral problems in the study population was 10.5%, compared to 38.7% in 1978. The specific nature and distribution of oral problems by diagnosis, by patient's age, and by type were remarkably consistent. Our results suggest that early and aggressive dental intervention in standardized protocols reduces the frequency of oral problems associated with cancer therapy.

Citing Articles

A systematic review of dentists' knowledge, perception, practice and confidence in managing patients with cancers.

Low S, Holden A, Shaw J BMC Health Serv Res. 2024; 24(1):1277.

PMID: 39443974 PMC: 11515570. DOI: 10.1186/s12913-024-11676-8.


Retrospective analysis of the effects of impacted third molar on hematologic patients undergoing hematopoietic stem cell transplantation.

Zhao S, Gao X, Wang S, Sun Y, Gao C Heliyon. 2024; 10(11):e32502.

PMID: 38961967 PMC: 11219483. DOI: 10.1016/j.heliyon.2024.e32502.


Dental Evaluation Prior to Cancer Therapy.

Yong C, Robinson A, Hong C Front Oral Health. 2022; 3:876941.

PMID: 35510226 PMC: 9058061. DOI: 10.3389/froh.2022.876941.


Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.

Niikura N, Nakatukasa K, Amemiya T, Watanabe K, Hata H, Kikawa Y Oncologist. 2020; 25(2):e223-e230.

PMID: 32043762 PMC: 7011665. DOI: 10.1634/theoncologist.2019-0382.


Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study.

Garcia-Chias B, Figuero E, Castelo-Fernandez B, Cebrian-Carretero J, Cerero-Lapiedra R Support Care Cancer. 2019; 27(9):3479-3490.

PMID: 30675665 DOI: 10.1007/s00520-019-4650-6.